NEW YORK (Reuters Health) – Dual anti-HER2 treatment with pertuzumab plus trastuzumab appears well tolerated and gives promising results in certain patients with HER2-positive advanced cancer of the biliary tract, according to an analysis of data from the MyPathway study….